-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240

Benzinga·10/07/2026 17:08:02
Diffusion vocale
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $239 to $240.